Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using RU58841 as a topical treatment for hair loss, with some users reporting no systemic issues. The original poster is considering RU58841 due to limited progress with dutasteride and oral minoxidil.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user noticed potential hair growth after 13 days of using RU58841, alongside a regimen of oral minoxidil, finasteride, and topical minoxidil. Others think it's too soon to see results, and some are surprised by the high dosage of oral minoxidil.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

A 15-year-old experiencing severe diffuse thinning plans to use minoxidil, dermarolling, and possibly ketoconazole, with hopes to later incorporate finasteride. Concerns about starting finasteride too young and the need for a dermatologist consultation are discussed.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

RU58841 may cause initial hair thinning, but improvement is possible over time. Users discuss experiences with Minoxidil and finasteride as additional treatments.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

An 18-year-old noticed hairline retreat at 17.5 and is seeking advice on whether to accept baldness or try treatments like Minoxidil, finasteride, or RU58841. They are concerned about safety and effectiveness at their age.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.

A 21-year-old male has been experiencing persistent hair loss despite using treatments like dutasteride, finasteride, RU58841, minoxidil, and ketoconazole. Suggestions include checking for hormonal issues, nutritional deficiencies, or allergies, and consulting a doctor for professional advice.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

Hair loss discussion; treatments include 0.5mg finasteride daily and 1.5mm dr pen weekly on scalp. Monthly progress updates planned.

The user shared their hair regrowth progress using a combination of treatments including finasteride, dutasteride, minoxidil, tretinoin, Sulfogenz, KX-826, low-level laser therapy, and microneedling. They plan to continue medication for another year before considering a hair transplant, noting steady improvement but not major changes.

The user added RU58841 to their finasteride and minoxidil routine, noticing significant improvement in hairline after 52 days. Some users warn about potential side effects of RU58841, while others express curiosity and congratulate the progress.

A user shared their 1.5-year progress after a FUE crown transplant, using dutasteride and oral minoxidil, which improved their hairline and stabilized hair loss. They experienced dizziness from topical minoxidil but had no side effects from finasteride, dutasteride, or oral minoxidil.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation is about seeking hairline regrowth results using RU58841, dermarolling, and Nizoral. The user cannot tolerate finasteride and finds minoxidil ineffective.